Quantitative evaluation of brain perfusion MRI with gadobutrol

Quantitative evaluation of brain perfusion MRI with gadobutrol - Quantitative evaluation of brain perfusion MRI with gadobutrol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026565

Enrollment

Registered

2017-03-15

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor

Interventions

gadobutrol 1.0 M at injection rate of 1.5mL/s gadoterate meglumine 0.5 M at injection rate of 3.0 mL/s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.patient who is performed DSC brain MRI with contrast media 2.adult (20 years old or older) at the time of aquisition of informed consent 3.obtained informed consent

Exclusion criteria

Exclusion criteria: 1.patients with contraindication for MRI 2.patients with contraindication for Gd contrast media 3.patients with CKD(eGFR<30 mL/min/1.73m2) 4.pregnant patient 5.patient who is being treated for asthma 6.any others judged ineligible as a subject by the investigator

Design outcomes

Primary

Measure	Time frame
comparison between MCRs (maximum signal change ratio) with gadobutrol and gadoterate meglumine of normal region in both white matter and gray matter	—

Secondary

Measure	Time frame
comparison between MCRs (maximum signal change ratio), CBV (cerebral blood volume), CBF(cerebral blood flow), histogram with gadobutrol and gadoterate meglumine of tumor regions	—

Countries

Japan

Contacts

Public ContactKohsuke Kudo

Hokkaido University Hospital Department of Diagnositic and Interventional Radiology

kkudo@huhp.hokudai.ac.jp011-706-5977

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026